The National Pharmaceutical Regulatory Agency (NPRA) has approved the clinical study of a new vaccine from China to be carried out in Malaysia. In a statement today, health director-general Tan Sri Dr Noor Hisham Abdullah said the clinical study will involve the SARS-CoV-2 vaccine (Vero Cells), inactivated, manufactured by Shenzhen Kangtai Biological Products Co Ltd in China.
Health experts say it is imperative for Malaysian authorities to speed up mass vaccinations, as soaring COVID-19 cases have prompted a nationwide lockdown starting on Tuesday.